摘要 |
The present invention relates to a method of treatment of a condition or disease selected from the group consisting of hypertension, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopahty, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, antheroscleorosis, angina (whether unstable or stable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis, scleroderma, glomecular sclerosis, proteinuria of primary renal disease,and also renal vascular hypertension, diabetic retinophathy, the management of other vascular disorders, such as migraine, peripheral vascular disease, Raynaud´s disease, luminal hyperplasia, endothelial dysfunction, cognitive dysfunction( such as Alzheimer's), glaucoma and stroke, comprising administering, to a mammal in need thereof, a therapeutically effective amount of a combination comprising (i) an ACE inhibitor, (ii) a calcium channel blocker (CCB), and (iii) a diuretic.
|
申请人 |
NOVARTIS AG.;NOVARTIS PHARMA GMBH;GRIGORIEFF, MELISSA;SHETTY, SURAJ, SHIVAPPA;WEBB, RANDY, LEE |
发明人 |
GRIGORIEFF, MELISSA;SHETTY, SURAJ, SHIVAPPA;WEBB, RANDY, LEE |